Revenue: As of FY2026 Q2, the actual value is USD 5.841 M.

EPS: As of FY2026 Q2, the actual value is USD -1.22.

EBIT: As of FY2026 Q2, the actual value is USD -53.65 M.

Financial Position

uniQure N.V. reported cash, cash equivalents, and current investment securities of $810.3 million as of June 30, 2026, an increase from $622.5 million as of December 31, 2025. Total assets were $985,103 thousand as of June 30, 2026, compared to $824,908 thousand as of December 31, 2025. Total liabilities increased to $661,053 thousand from $626,007 thousand over the same period. Total shareholders’ equity stood at $324,050 thousand on June 30, 2026, up from $198,901 thousand on December 31, 2025.

Revenue

Revenue for the three months ended June 30, 2026, was $5.8 million, an increase of $0.5 million compared to $5.3 million in the same period of 2025. This increase was primarily attributed to higher license revenue.

Operating Expenses

Research and development (R&D) expenses were - $34.0 million for the three months ended June 30, 2026, which was a - $1.4 million decrease from - $35.4 million in the prior year’s period. This decrease was driven by a - $3.2 million reduction in other R&D expenses, partially offset by a + $1.8 million increase in direct R&D expenses. Selling, general and administrative (SG&A) expenses were - $17.4 million for the three months ended June 30, 2026, an increase of + $3.9 million from - $13.5 million in the same period of 2025. This rise was mainly due to a + $4.3 million increase in employee and contractor-related expenses, including share-based compensation, to support the potential commercial launches of AMT-130.

Other Expense

Other expense increased to - $8.0 million for the three months ended June 30, 2026, from - $2.2 million in the corresponding period of 2025, primarily due to a + $6.0 million increase in costs associated with the supply of HEMGENIX® to CSL Behring.

Other Non-Operating Items, Net

Other non-operating items, net, resulted in an expense of - $27.0 million for the three months ended June 30, 2026, a significant change from a gain of + $6.6 million in the same period of 2025. This - $33.6 million increase in net non-operating expense was mainly related to a - $20.4 million unfavorable change in net foreign currency and a - $16.0 million loss from changes in the fair value of the liability related to pre-funded warrants.

Net Loss

The net loss for the three months ended June 30, 2026, was - $81.1 million, or - $1.22 basic and diluted loss per ordinary share, compared to a net loss of - $37.7 million, or - $0.69 basic and diluted loss per ordinary share, for the comparative period in 2025.

Operational Metrics

uniQure N.V. completed an upsized underwritten public offering in June 2026, generating aggregate gross proceeds of $259 million, which included the full exercise of the underwriters’ option to purchase additional shares.

Outlook / Guidance

uniQure N.V. anticipates submitting its Biologics License Application (BLA) for AMT-130 for Huntington’s disease in the third quarter of 2026, with U.S. and U.K. regulatory submissions on track as planned. The company expects to present topline four-year data from the Phase I/II study of AMT-130 in September 2026 and plans to initiate a confirmatory study expeditiously after aligning with the FDA on the trial design. uniQure N.V. projects its current financial resources will be sufficient to fund projected operating expenses into 2030, supporting the anticipated commercial launch of AMT-130 and continued pipeline investment.